Literature DB >> 22575599

Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.

Fabrice Billet1, Jean Costentin, Nathalie Dourmap.   

Abstract

Chronic L-3,4-dihydroxyphenylalanine (L-DOPA) treatment of Parkinson's disease induces in time numerous side effects, such as abnormal involuntary movements called L-DOPA-induced dyskinesias (LIDs). An involvement of glutamate transmission, dopamine transmission and opioid transmission in striatal output pathways has been hypothesized for the induction of LIDs. Interestingly, our previous experiments indicated that some striatal δ-opioid receptors are located on terminals of glutamatergic corticostriatal neurons and that stimulation of these receptors modulates the release of glutamate and dopamine. The present study was performed to test the involvement of δ-opioid receptors, and more precisely of those located on corticostriatal neurons, in abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats. The effects of a selective agonist, [D-Pen(2), D-Pen(5)]-enkephalin (DPDPE) and a selective antagonist (naltrindole) of δ-opioid receptors on LIDs were investigated in animals submitted or not to a corticostriatal deafferentation. Our results indicate that DPDPE and naltrindole respectively enhanced and reduced LIDs in animals in which the ipsilateral cortex was preserved intact. However, the lesion of the ipsilateral cortex prevented the stimulant effect of DPDPE on LIDs. The [(3)H]-DPDPE binding to striatal membranes prepared from the whole striatum was also studied. A significant increase in density of δ-opioid receptors was found in the striatum of dyskinetic animals as compared to non-dyskinetic animals but this difference was abolished by the corticostriatal deafferentation. These results indicate that δ-opioid transmission modulates the expression of LIDs in rodents and suggest that the δ-opioid receptors involved in this effect are located on terminals of corticostriatal neurons.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575599     DOI: 10.1016/j.expneurol.2012.04.017

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

Review 1.  Animal models of Parkinson's disease: a gateway to therapeutics?

Authors:  Weidong Le; Pavani Sayana; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 2.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

Review 3.  Delta opioid receptors in brain function and diseases.

Authors:  Paul Chu Sin Chung; Brigitte L Kieffer
Journal:  Pharmacol Ther       Date:  2013-06-10       Impact factor: 12.310

4.  Synergistic activity between the delta-opioid agonist SNC80 and amphetamine occurs via a glutamatergic NMDA-receptor dependent mechanism.

Authors:  Kelly E Bosse; Emily M Jutkiewicz; Kristin N Schultz-Kuszak; Omar S Mabrouk; Robert T Kennedy; Margaret E Gnegy; John R Traynor
Journal:  Neuropharmacology       Date:  2013-09-10       Impact factor: 5.250

Review 5.  Opioidergic Modulation of Striatal Circuits, Implications in Parkinson's Disease and Levodopa Induced Dyskinesia.

Authors:  Stefania Sgroi; Raffaella Tonini
Journal:  Front Neurol       Date:  2018-07-05       Impact factor: 4.003

Review 6.  Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Authors:  Fabio Del Bello; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia
Journal:  Biomolecules       Date:  2019-04-09

Review 7.  Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.

Authors:  Carla Ferreira; Catarina Almeida; Sandra Tenreiro; Alexandre Quintas
Journal:  Life (Basel)       Date:  2020-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.